Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00222794
Status:
COMPLETED
Last Update Posted:
2010-08-31
First Post:
2005-09-08
Brief Title:
A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
A Randomized Parallel Group Double Blind Placebo Controlled Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study proposes to examine the effect of atomoxetine on quality of life and negative symptoms such as social withdrawal lack of interest in things lack of thought content flat emotions slowed body movements and lack of drive and motivation in patients with schizophrenia or schizoaffective disorder This study also examines the safety of using atomoxetine along with the conventional antipsychotic in these patients
Detailed Description:
This study proposes to examine the effect of Atomoxetine Strattera a selective norepinephrine reuptake inhibitor on Negative Symptoms and Quality of Life and its safety when used in conjunction with an atypical antipsychotic agent in remitted community dwelling subjects with Schizophrenia or Schizoaffective disorder Atomoxetine was recently approved by the FDA for the treatment of Attention Deficit Hyperactivity Disorder in children and adults All subjects will receive various psychometric assessments at 2-week intervals for a period of 26 weeks It is hypothesized that subjects treated with Atomoxetine in this 26 week random assignment parallel-group double-blind placebo-controlled study will have a significantly greater improvement in quality of life and social functioning
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 03T-327 | None | None | None |